Lowenstein Sandler represented Matinas BioPharma Holdings, Inc. (MTNB-OTCQB) in connection with a $10 million private placement, which closed on April 10, 2015. Matinas sold to accredited investors an aggregate of 20,000,000 units at a price of $0.50 per unit, with each unit consisting of one share of the Company's common stock and a five-year warrant to purchase one share of common stock at an exercise price of $0.75 per share. SternAegis Ventures, through Aegis Capital Corp., acted as the exclusive Placement Agent for the offering. The Lowenstein deal team was led by Steven M. Skolnick, Michael J. Lerner, Meredith Prithviraj, Irina Ishak and Robert Bee, Jr.